Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
887 2 |
Ultima descărcare din IBN: 2018-08-20 23:48 |
SM ISO690:2012 REVENCO, Valeriu, OCHIŞOR, Viorica, MIHALACHE, Georgeta, GRIB, Liviu, GRĂJDIERU, Romeo. Particularităţi hemodinamice,antropometrice
şi metabolice la pacienţii cu hipertensiune arterială în funcţie de obezitate şi influenţa agonistului receptorilor imidazolinici i1 – moxonidine asupra unor
indici ai hemodinamicii şi insulinorezistenţei
. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2010, nr. 2(25), pp. 45-48. ISSN 1857-0011. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale | ||||||
Numărul 2(25) / 2010 / ISSN 1857-0011 | ||||||
|
||||||
Pag. 45-48 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Au fost evaluaţi 121 de pacienţi cu HTA gr. I-II, în funcţie de obezitate. Studiul a demonstrat că la
pacienţii hipertensivi obezi mai frecvent a fost constatată HTA gr. II, diabetul zaharat tip 2 şi valori sporite
ale indicilor insulinorezistenţei. Moxonidine a redus TAS cu 18,3±1,1 mmHg, TAD cu 6,6±0,5 mmHg şi nu a
infl uenţat semnifi cativ FCC. La pacienţii cu HTA gr. I-II moxonidine (0,4 mg/24 ore), administrat în tratament
de durată timp de 8 săptămâni, a îmbunătăţit indicii insulinorezistenţei prin reducerea insulinei ulrasenzitive
bazale şi diminuarea indicelui HOMAIR |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-11052</cfResPublId> <cfResPublDate>2010-03-02</cfResPublDate> <cfVol>25</cfVol> <cfIssue>2</cfIssue> <cfStartPage>45</cfStartPage> <cfISSN>1857-0011</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/11052</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Particularităţi hemodinamice,antropometrice şi metabolice la pacienţii cu hipertensiune arterială în funcţie de obezitate şi influenţa agonistului receptorilor imidazolinici i1 – moxonidine asupra unor indici ai hemodinamicii şi insulinorezistenţei </cfTitle> <cfAbstr cfLangCode='RO' cfTrans='o'>Au fost evaluaţi 121 de pacienţi cu HTA gr. I-II, în funcţie de obezitate. Studiul a demonstrat că la pacienţii hipertensivi obezi mai frecvent a fost constatată HTA gr. II, diabetul zaharat tip 2 şi valori sporite ale indicilor insulinorezistenţei. Moxonidine a redus TAS cu 18,3±1,1 mmHg, TAD cu 6,6±0,5 mmHg şi nu a infl uenţat semnifi cativ FCC. La pacienţii cu HTA gr. I-II moxonidine (0,4 mg/24 ore), administrat în tratament de durată timp de 8 săptămâni, a îmbunătăţit indicii insulinorezistenţei prin reducerea insulinei ulrasenzitive bazale şi diminuarea indicelui HOMAIR</cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'>During the study 121 patients were evaluated with hypertension I-II degree in relation with obesity. The study showed that patients with hypertension and obesity have more frequently II degree hypertension, diabetes mellitus type 2, and increased values of insulin resistance indexes. Moxonidine decreased systolic blood pressure with 18,3±1,1 mmHg, diastolic blood pressure with 6,6±0,5 mmHg and did not infl uence signifi cantly heart rate. For the patients with I-II degree hypertension, moxonidine (0,4 mg/24 hours), administered for 8 weeks, improved the insulin resistance indexes by decreasing the ultrasensitive basal insulin and decreasing the HOMAIR index.</cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'>Были исследованны 121 пациентов с гипертонической болезнью I-II ст., в зависимости от ожирения. У пациентов с гипертонической болезнью с ожирением чаще была выявлена ГБ II-й ст., чаще был выявлен сахарный диабет 2-го типа, повышенные показатели инсулинорезистентности. Моксонидин снизил САД на 18,3±1,1 mmHg, ДАД на 6,6±0,5 mmHg, незначительнo повлиял на ЧСС. У пациентов с ГБ I-II ст. в зависимости ожирения, моксонидин (0,4 мг/день - 8 недель) улучшил некоторые показатели инсулинорезистентности (базальный инсулин, индекс HOMAIR).</cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11771</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11442</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-26984</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11112</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11107</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11771</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11771-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> <cfFamilyNames>Revenco</cfFamilyNames> <cfFirstNames>Valeriu</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11442</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11442-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> <cfFamilyNames>Ochişor</cfFamilyNames> <cfFirstNames>Viorica</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-26984</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-26984-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> <cfFamilyNames>Mihalache</cfFamilyNames> <cfFirstNames>Georgeta</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11112</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11112-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> <cfFamilyNames>Grib</cfFamilyNames> <cfFirstNames>Liviu</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11107</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11107-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2010-03-02T24:00:00</cfStartDate> <cfFamilyNames>Grăjdieru</cfFamilyNames> <cfFirstNames>Romeo</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>